PHARMACOKINETIC STUDY OF SPARFLOXACIN IN PATIENTS RECEIVING REGULAR HEMODIALYSIS

We investigated the in vivo kinetics of sparfloxacin (SPFX), an oral quinolone, in the hemodialytic patients. SPFX was orally administrated in a single dose of 200 mg to each of five hemodialytic patients, on a day that they were not receiving hemodialysis therapy. After dosing, the blood samples we...

Full description

Saved in:
Bibliographic Details
Published in:Japanese journal of antibiotics 1995/08/25, Vol.48(8), pp.999-1002
Main Authors: AOKI, NOBUKI, KOUDA, YUTAKA, YOSHIKAWA, HIROKO, USUDA, YOSHIMARU
Format: Article
Language:Japanese
Subjects:
Administration, Oral
Aged
Aged, 80 and over
Anti-Infective Agents - administration & dosage
Anti-Infective Agents - pharmacokinetics
Female
Fluoroquinolones
Half-Life
Humans
Kidney Failure, Chronic - metabolism
Male
Middle Aged
Quinolones - administration & dosage
Quinolones - pharmacokinetics
Renal Dialysis
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We investigated the in vivo kinetics of sparfloxacin (SPFX), an oral quinolone, in the hemodialytic patients. SPFX was orally administrated in a single dose of 200 mg to each of five hemodialytic patients, on a day that they were not receiving hemodialysis therapy. After dosing, the blood samples were collected periodically at 2, 4, 6, 8, 12, 24, 25, 27, 29, 48, 72 hours. Concentration of the unchanged SPFX in the plasma samples were measured by HPLC. The peak plasma levels of SPFX in the hemodialytic patients did not differ greatly from patients with renal failure (5
ISSN:0368-2781
2186-5477
DOI:10.11553/antibiotics1968b.48.999